Literature DB >> 20622834

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India.

Swathi Padmanabhan1, Tahir Amin, Bhaven Sampat, Robert Cook-Deegan, Subhashini Chandrasekharan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20622834      PMCID： PMC3138722          DOI： 10.1038/nbt0710-671

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  22 in total

Review 1.  Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.

Authors:  Amie Batson; Filip Meheus; Steve Brooke
Journal:  Vaccine       Date:  2006-06-06       Impact factor: 3.641

2.  Introducing HPV vaccine in developing countries--key challenges and issues.

Authors:  Jan M Agosti; Sue J Goldie
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

3.  Market-based licensing for HPV vaccines in developing countries.

Authors:  Kevin Outterson; Aaron S Kesselheim
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

4.  The GO License: only part of the solution.

Authors:  Amie Batson; Julie B Milstien
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

Review 5.  Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?

Authors:  P Lydon; R Levine; M Makinen; L Brenzel; V Mitchell; J B Milstien; L Kamara; S Landry
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

6.  Latin America. Price is the main barrier to wider use of papillomavirus vaccine.

Authors:  Jocelyn Kaiser
Journal:  Science       Date:  2008-05-16       Impact factor: 47.728

7.  NIH forges R&D partnerships in developing countries.

Authors:  Luis A Salicrup
Journal:  Nat Biotechnol       Date:  2007-09       Impact factor: 54.908

Review 8.  Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.

Authors:  Rengaswamy Sankaranarayanan; Neerja Bhatla; Patti E Gravitt; Partha Basu; Pulikattil O Esmy; K S Ashrafunnessa; Yasantha Ariyaratne; Aarati Shah; Bhagwan M Nene
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

9.  Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.

Authors:  Sue J Goldie; Meredith O'Shea; Mireia Diaz; Sun-Young Kim
Journal:  Reprod Health Matters       Date:  2008-11

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506
View more
  15 in total

1.  Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

Authors:  N Hanumantha Rao; P Baji Babu; L Rajendra; R Sriraman; Yuk-Ying S Pang; John T Schiller; V A Srinivasan
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

2.  Access to new technologies in multipatented vaccines: challenges for Brazil.

Authors:  Cristina Possas; Adelaide Maria de Souza Antunes; Flavia Maria Lins Mendes; Suzanne de Oliveira Rodrigues Schumacher; Reinaldo Menezes Martins; Akira Homma
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

3.  It is time to accelerate building local vaccine adjuvant manufacturing capacity.

Authors:  Christopher B Fox
Journal:  Ther Adv Vaccines Immunother       Date:  2017-10-09

4.  Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways.

Authors:  Sara Eve Crager
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

5.  University Technology Transfer Has Failed to Improve Access to Global Health Products during the COVID-19 Pandemic.

Authors:  Matthew Herder; E Richard Gold; Srinivas Murthy
Journal:  Healthc Policy       Date:  2022-05

Review 6.  Making HPV vaccination available to girls everywhere.

Authors:  Austin M Oberlin; Lisa Rahangdale; Lameck Chinula; Nurain M Fuseini; Carla J Chibwesha
Journal:  Int J Gynaecol Obstet       Date:  2018-09-12       Impact factor: 3.561

7.  Global challenges of implementing human papillomavirus vaccines.

Authors:  Janice E Graham; Amrita Mishra
Journal:  Int J Equity Health       Date:  2011-06-30

Review 8.  Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.

Authors:  Emma Rey-Jurado; Felipe Tapia; Natalia Muñoz-Durango; Margarita K Lay; Leandro J Carreño; Claudia A Riedel; Susan M Bueno; Yvonne Genzel; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-01-18       Impact factor: 7.561

Review 9.  Current status of human papillomavirus vaccines.

Authors:  Kwang Sung Kim; Shin Ae Park; Kyung-Nam Ko; Seokjae Yi; Yang Je Cho
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20

10.  Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.

Authors:  Nicole G Campos; Monisha Sharma; Andrew Clark; Jane J Kim; Stephen C Resch
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.